The global fecal pancreatic elastase testing market has a significant growth predicted, rising from USD 15,306.7 million in 2023 to USD 31,842.3 million in 2033. Between 2023 and 2033, the market is projected to expand at a strong compound annual growth rate (CAGR) of 7.6%.
Pancreatic exocrine insufficiency (PEI), a disorder marked by insufficient pancreatic enzyme synthesis, is the main diagnosis made by fecal pancreatic elastase testing. Fecal pancreatic elastase testing is one of several trustworthy and accurate diagnostic methods that will likely be in high demand worldwide as awareness of gastrointestinal issues and pancreatic diseases grows.
Lead With Intelligence: Report Sample Awaits:
https://www.futuremarketinsights.com/reports/sample/rep-gb-14507
Rising Pancreatic Cancer Rates:
Several factors contribute to the increasing prevalence of pancreatic cancer, including:
- Obesity and Physical Inactivity: These lifestyle factors are linked to an elevated risk of developing pancreatic cancer.
- Dietary Habits: A high-fat diet low in vegetables and high in red and processed meat consumption can increase pancreatic cancer risk.
Improved Treatment Options Spark Optimism:
New developments in therapeutic possibilities provide a glimmer of optimism despite the obstacles. Patients with pancreatic cancer are seeing longer life times thanks to the discovery of novel medication regimens and combinations.
Focus on Early Detection Remains Key:
Even though there are potential new treatment options, improving patient outcomes still heavily depends on early detection. The market for fecal pancreatic elastase testing is essential to this battle since it offers a non-invasive instrument for early detection and better patient care.
Competitive Landscape:
Manufacturers employ a number of crucial strategies to increase their clientele. Including the introduction of new products, developments in technology, collaborations, and distribution contracts amongst industry players.
Recent Development:
- In June 2020, BÜHLMANN unveiled the BÜHLMANN fPELA® turbo, a revolutionary turbidimetric immunoassay. It has received CE certification and is intended to speed up the detection of human pancreatic elastase.
- Pancreatic Elastase-Turbidimetric test, a quantitative turbidimetric test for the detection of human Pancreatic Elastase E1 in human solid stool samples. It was introduced by Vitassay, a developer and distributor of diagnostic tests, in May 2020.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-14507
Some Key Companies are as follows:
- Laboratory Corporation of America® Holdings
- DiaSorin
- ScheBo Biotech AG
- Immundiagnostik AG
- Invivo Healthcare
- DRG Instruments GMBH
- Verisana Laboratories
- BÜHLMANN Laboratories AG
- CerTest Biotec S.L.
- R-Biopharm AG
- American Laboratory Products Company, Ltd.
- Vitassay Healthcare, S.L.U.
Key Segments Covered in the Market:
By Product:
- Fecal Pancreatic Elastase ELISA Kits
- Rapid Fecal Pancreatic Elastase Kits
By Indication:
- Chronic Pancreatitis
- Type 1 Diabetes
- Cystic Fibrosis
- Others
By End User:
- Hospitals
- Diagnostics Laboratories
- Specialty Clinics
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa
In-Depth Market Overview: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/14507
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube